{Reference Type}: Journal Article
{Title}: Hippocampal avoidance whole-brain radiotherapy with simultaneous integrated boost in lung cancer brain metastases and utility of the Hopkins verbal learning test for testing cognitive impairment in Chinese patients: a prospective phase II study.
{Author}: Li Z;Wang J;Deng L;Zhai Y;Zhang T;Bi N;Wang J;Wang X;Liu W;Xiao Z;Chen D;Lv J;Feng Q;Wang W;Zhou Z;
{Journal}: BMC Cancer
{Volume}: 24
{Issue}: 1
{Year}: 2024 Jul 26
{Factor}: 4.638
{DOI}: 10.1186/s12885-024-12559-1
{Abstract}: <B>BACKGROUND: </B>This study aimed to evaluate the efficiency of hippocampal avoidance whole-brain radiotherapy with a simultaneous integrated boost (HA-WBRT-SIB) treating brain metastases (BM) and utility of the Hopkins Verbal Learning Test-Revised (HVLT-R) (Chinese version) in Chinese lung cancer patients.<BR><B>METHODS: </B>Lung cancer patients with BM undergone HA-WBRT-SIB at our center were enrolled. Brain magnetic resonance imaging, The HVLT total learning score, and side effects were evaluated before radiotherapy and 1, 3, 6, and 12 months after radiotherapy. This study analyzed the overall survival rate, progression-free survival rate, and changes in HVLT-R immediate recall scores.<BR><B>RESULTS: </B>Forty patients were enrolled between Jan 2016 and Jan 2020. The median follow-up time was 14.2 months. The median survival, progression-free survival, and intracranial progression-free survival of all patients were 14.8 months, 6.7 months and 14.8 months, respectively. Multivariate analysis indicated that male sex and newly diagnosed stage IV disease were associated with poor overall survival and progression-free survival, respectively. HVLT-R scores at baseline and 1, 3, and 6 months after radiotherapy were 21.94 ± 2.99, 20.88 ± 3.12, 20.03 ± 3.14, and 19.78 ± 2.98, respectively. The HVLT-R scores at 6 months after radiotherapy decreased by approximately 9.8% compared with those at baseline. No grade 3 toxicities occurred in the entire cohort.<BR><B>CONCLUSIONS: </B>HA-WBRT-SIB is of efficiency and cognitive-conserving in treating Chinese lung cancer BM.<BR><B>BACKGROUND: </B>This study was retrospectively registered on ClinicalTrials.gov in 24th Feb, 2024. The ClinicalTrials.gov ID is NCT06289023.